ID   NCI-H2052
AC   CVCL_1518
SY   H2052; H-2052; H2052_MM; NCIH2052
DR   CLO; CLO_0008042
DR   EFO; EFO_0002275
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5915
DR   BioSample; SAMN03471041
DR   BioSample; SAMN03472597
DR   BioSample; SAMN10987937
DR   BioSamples; SAMEA100851
DR   CCLE; NCIH2052_PLEURA
DR   Cell_Model_Passport; SIDM00713
DR   ChEMBL-Cells; CHEMBL3308119
DR   ChEMBL-Targets; CHEMBL1075531
DR   Cosmic; 688058
DR   Cosmic; 877272
DR   Cosmic; 877437
DR   Cosmic; 886390
DR   Cosmic; 980998
DR   Cosmic; 1032389
DR   Cosmic; 1146898
DR   Cosmic; 1481545
DR   Cosmic; 1522774
DR   Cosmic; 1541213
DR   Cosmic; 1571797
DR   Cosmic; 1749565
DR   Cosmic; 1891920
DR   Cosmic; 1963327
DR   Cosmic; 1995554
DR   Cosmic; 2474148
DR   Cosmic-CLP; 688058
DR   DepMap; ACH-000153
DR   GDSC; 688058
DR   GEO; GSM434305
DR   GEO; GSM726264
DR   GEO; GSM794345
DR   GEO; GSM850299
DR   GEO; GSM887398
DR   GEO; GSM888476
DR   GEO; GSM1670209
DR   IARC_TP53; 21553
DR   IGRhCellID; H2052_MMGEO
DR   IGRhCellID; NCIH2052
DR   LiGeA; CCLE_326
DR   PharmacoDB; NCIH2052_1059_2019
DR   Wikidata; Q54907907
RX   PubMed=8806092;
RX   PubMed=10987304;
RX   PubMed=11030152;
RX   PubMed=11314036;
RX   PubMed=16630136;
RX   PubMed=17270034;
RX   PubMed=19853261;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20624269;
RX   PubMed=21245096;
RX   PubMed=21642991;
RX   PubMed=22460905;
RX   PubMed=23830731;
RX   PubMed=24926545;
RX   PubMed=25485619;
RX   PubMed=25902174;
RX   PubMed=25984343;
RX   PubMed=26011428;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28553954;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 48 hours (PubMed=25984343).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for CDKN2A deletion (PubMed=16630136).
CC   Sequence variation: Homozygous for LATS2 deletion (PubMed=21245096).
CC   Sequence variation: NF2 p.Arg341Ter (c.1021C>T) (PubMed=16630136; PubMed=25902174).
CC   Sequence variation: RASSF2 p.Glu294Ter (c.G880T) (PubMed=25902174).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=31068700).
CC   Sequence variation: Has no TP53 mutation (CCLE; Cosmic-CLP).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.17%; Native American=0%; East Asian, North=2.33%; East Asian, South=0%; South Asian=0.22%; European, North=64.49%; European, South=32.79% (PubMed=30894373).
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 11,13
ST   D18S51: 17
ST   D21S11: 32.2
ST   D3S1358: 14,15
ST   D5S818: 11
ST   D7S820: 12 (ATCC; Cosmic-CLP)
ST   D7S820: 11,12 (PubMed=25877200)
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 10
ST   Penta E: 12,16
ST   TH01: 7,9.3
ST   TPOX: 8,11 (ATCC; Cosmic-CLP)
ST   TPOX: 8 (PubMed=25877200)
ST   vWA: 17
DI   NCIt; C45663; Pleural sarcomatoid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_2647 ! NCI-BL2052
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 30
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=10987304;
RA   Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.;
RT   "Genome-wide allelotyping of lung cancer identifies new regions of
RT   allelic loss, differences between small cell lung cancer and non-small
RT   cell lung cancer, and loci clustering.";
RL   Cancer Res. 60:4894-4906(2000).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x;
RA   Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S.,
RA   Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.;
RT   "Establishment and characterization of four malignant pleural
RT   mesothelioma cell lines from Japanese patients.";
RL   Cancer Sci. 97:387-394(2006).
//
RX   PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x;
RA   Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K.,
RA   Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M.,
RA   Sekido Y.;
RT   "Genomic profiling of malignant pleural mesothelioma with array-based
RT   comparative genomic hybridization shows frequent non-random
RT   chromosomal alteration regions including JUN amplification on 1p32.";
RL   Cancer Sci. 98:438-446(2007).
//
RX   PubMed=19853261; DOI=10.1016/j.jtcvs.2009.06.027;
RA   Hartman M.-L., Esposito J.M., Yeap B.Y., Sugarbaker D.J.;
RT   "Combined treatment with cisplatin and sirolimus to enhance cell death
RT   in human mesothelioma.";
RL   J. Thorac. Cardiovasc. Surg. 139:1233-1240(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20624269; DOI=10.1186/1756-9966-29-75;
RA   Du L., Schageman J.J., Irnov I., Girard L., Hammond S.M., Minna J.D.,
RA   Gazdar A.F., Pertsemlidis A.;
RT   "MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells
RT   and suggests a possible pathological relationship between SCLCs and
RT   NSCLCs.";
RL   J. Exp. Clin. Cancer Res. 29:75-75(2010).
//
RX   PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164;
RA   Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T.,
RA   Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H.,
RA   Sekido Y.;
RT   "LATS2 is a tumor suppressor gene of malignant mesothelioma.";
RL   Cancer Res. 71:873-883(2011).
//
RX   PubMed=21642991; DOI=10.1038/ng.855;
RA   Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L.,
RA   Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R.,
RA   Powell S., Zhou Q., Shen R., Olshen A.B., Rusch V., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006;
RA   Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y.,
RA   Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.;
RT   "Integrated high-resolution array CGH and SKY analysis of homozygous
RT   deletions and other genomic alterations present in malignant
RT   mesothelioma cell lines.";
RL   Cancer Genet. 206:191-205(2013).
//
RX   PubMed=24926545; DOI=10.1097/JTO.0000000000000202;
RA   Riquelme E., Suraokar M.B., Rodriguez J., Mino B., Lin H.Y.,
RA   Rice D.C., Tsao A., Wistuba I.I.;
RT   "Frequent coamplification and cooperation between C-MYC and PVT1
RT   oncogenes promote malignant pleural mesothelioma.";
RL   J. Thorac. Oncol. 9:998-1007(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28553954; DOI=10.1038/onc.2017.147;
RA   Kato T., Sato T., Yokoi K., Sekido Y.;
RT   "E-cadherin expression is correlated with focal adhesion kinase
RT   inhibitor resistance in merlin-negative malignant mesothelioma
RT   cells.";
RL   Oncogene 36:5522-5531(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402(2020).
//